Smooth muscle cell mineralocorticoid receptors: Role in vascular function and contribution to cardiovascular disease

Pflugers Archiv European Journal of Physiology

Volumn 465, Issue 12, 2013, Pages 1661-1670

  McCurley, Amy ^a   McGraw, Adam ^a   Pruthi, Dafina ^a   Jaffe, Iris Z ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Atherosclerosis; Hypertension; Inflammation; Mineralocorticoid receptor (MR); Vascular aging; Vascular remodeling

Indexed keywords

ALKALINE PHOSPHATASE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN E; BONE MORPHOGENETIC PROTEIN 2; CALCIUM CHANNEL; CELL ADHESION MOLECULE; CHEMOKINE; CIGARETTE SMOKE; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR; EPLERENONE; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 5; MATRIX PROTEIN; MEMBRANE RECEPTOR; METALLOTHIONEIN I; METALLOTHIONEIN II; MINERALOCORTICOID RECEPTOR; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SPIRONOLACTONE; STEROID RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADIPOCYTE; ANGIOPLASTY; AORTA ARCH; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD FLOW; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BLOOD VESSEL CALCIFICATION; BLOOD VESSEL INJURY; BLOOD VESSEL REACTIVITY; BLOOD VESSEL WALL; BLOOD VOLUME; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CALCIUM SIGNALING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CAROTID ARTERY FIBROSIS; CAROTID ENDOTHELIAL INJURY; CELL CYCLE REGULATION; CELL MIGRATION; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS SURGERY; DEATH; DEPHOSPHORYLATION; DEPRESSED BLOOD PRESSURE; DESCENDING AORTA; DIABETES MELLITUS; DIASTOLIC HEART FAILURE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; EXTRACELLULAR CALCIUM; EXTRACELLULAR MATRIX; FIBROBLAST; GENE CONTROL; GENE DUPLICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HIGH SODIUM INTAKE; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; INFLAMMATORY CELL; INTIMA; KIDNEY FAILURE; LEUKOCYTE; LIPID STORAGE; LYMPHOCYTIC INFILTRATION; MEMBRANE DEPOLARIZATION; MONOCYTE; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); NEUTROPHIL CHEMOTAXIS; NONHUMAN; OBESITY; ORGAN PERFUSION; OXIDATIVE STRESS; PATHOGENESIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHENOTYPE; PLAQUE RUPTURE; PORTAL HYPERTENSION; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN PROCESSING; RESISTANT HYPERTENSION; REVIEW; RISK FACTOR; RUPTURE; SALT WASTING; SMOKING; SMOOTH MUSCLE FIBER; SODIUM INTAKE; SODIUM RETENTION; STENT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; THROMBOSIS; UPREGULATION; VASCULAR FIBROSIS; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASCULARIZATION; VASCULITIS; VASOCONSTRICTION; WOUND HEALING;

AGING; ALDOSTERONE; ANGIOTENSIN II; ANIMALS; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CAROTID ARTERIES; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION; MICE; MUSCLE, SMOOTH, VASCULAR; PREGNANCY PROTEINS; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84890433237     PISSN: 00316768     EISSN: 14322013     Source Type: Journal    
DOI: 10.1007/s00424-013-1282-4     Document Type: Review

References (97)

1. Baker ME (2001) Adrenal and sex steroid receptor evolution: environmental implications. J Mol Endocrinol 26:119-125
2. Baldo MP, Forechi L, Morra EA, Zaniqueli D, Machado RC, Lunz W, Rodrigues SL, Mill JG (2011) Long-term use of low-dose spironolactone in spontaneously hypertensive rats: effects on left ventricular hypertrophy and stiffness. Pharmacol Rep 63(4):975-982
3. Batterink J, Stabler SN, Tejani AM, Fowkes CT (2010) Spironolactone for hypertension. Cochrane Database Syst Rev (8):CD008169
4. Baumann M, Megens R, Bartholome R, Dolff S, van Zandvoort MA, Smits JF, Struijker-Boudier HA, De Mey JG (2007) Prehypertensive renin-angiotensin- aldosterone system blockade in spontaneously hypertensive rats ameliorates the loss of long-term vascular function. Hypertens Res 30(9):853-861
5. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P et al (2009) Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 119(3):524-530
6. Berger S, Bleich M, Schmid W, Cole TJ, Peters J, Watanabe H, Kriz W, Warth R, Greger R, Schutz G (1998) Mineralocorticoid receptor knockout mice: pathophysiology of Na + metabolism. Proc Natl Acad Sci U S A 95(16):9424-9429
7. Berger S, Bleich M, Schmid W, Greger R, Schutz G (2000) Mineralocorticoid receptor knockout mice: lessons on Na + metabolism. Kidney Int 57(4):1295-1298
8. Bernini G, Galetta F, Franzoni F, Bardini M, Taurino C, Bernardini M, Ghiadoni L, Bernini M, Santoro G, Salvetti A (2008) Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens 26(12):2399-2405
9. Bhargava A, Wang J, Pearce D (2004) Regulation of epithelial ion transport by aldosterone through changes in gene expression. Mol Cell Endocrinol 217(1-2):189-196
10. Cassis P, Conti S, Remuzzi G, Benigni A (2010) Angiotensin receptors as determinants of life span. Pflugers Arch 459(2):325-332
11. Chugh G, Lokhandwala MF, Asghar M (2012) Altered functioning of both renal dopamine D1 and angiotensin II type 1 receptors causes hypertension in old rats. Hypertension 59(5):1029-1036
12. Croom KF, Perry CM (2005) Eplerenone: a review of its use in essential hypertension. Am J Cardiovasc Drugs 5(1):51-69
13. Dai G, Kaazempur-Mofrad MR, Natarajan S, Zhang Y, Vaughn S, Blackman BR, Kamm RD, Garcia-Cardena G, Gimbrone MA Jr (2004) Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature. Proc Natl Acad Sci U S A 101(41):14871-14876
14. Deuchar GA, McLean D, Hadoke PW, Brownstein DG, Webb DJ, Mullins JJ, Chapman K, Seckl JR, Kotelevtsev YV (2011) 11β-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice. Endocrinology 152(1):236-246
15. Funder JW, Mihailidou AS (2009) Aldosterone and mineralocorticoid receptors: clinical studies and basic biology. Mol Cell Endocrinol 301(1-2):2-6
16. Funder JW, Pearce PT, Smith R, Campbell J (1989) Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology 125(4):2224-2226
17. Gomez D, Owens GK (2012) Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res 95(2):156-164
18. Gradman AH (2009) Role of angiotensin II type 1 receptor antagonists in the treatment of hypertension in patients aged >65 years. Drugs Aging 26(9):751-767
19. Gronholdt ML, Dalager-Pedersen S, Falk E (1998) Coronary atherosclerosis: determinants of plaque rupture. Eur Heart J 19:C24-C29
20. Grossmann C, Krug AW, Freudinger R, Mildenberger S, Voelker K, Gekle M (2007) Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am J Physiol Endocrinol Metab 292(6):E1790-E1800
21. Hansson GK, Hermansson A (2011) The immune system in atherosclerosis. Nat Immunol 12(3):204-212
22. Hastings NE, Feaver RE, Lee MY, Wamhoff BR, Blackman BR (2009) Human IL-8 regulates smooth muscle cell VCAM-1 expression in response to endothelial cells exposed to atheroprone flow. Arterioscler Thromb Vasc Biol 29(5):725-731
23. Hillaert M, Lentjes EG, Kemperman H, van der Graaf Y, Nathoe HM, Beygui F, Montalescot G, Doevendans PA, Wassink AM, Van Belle E et al (2012) Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. Int J Cardiol. doi: 10.1016/j.ijcard.2012.05.034
24. Hillaert MA, Lentjes EG, Beygui F, Kemperman H, Asselbergs FW, Nathoe HM, Agostoni P, Voskuil M, Ivanes F, Jude B et al (2011) Measuring and targeting aldosterone and renin in atherosclerosis - a review of clinical data. Am Heart J 162(4):585-596
25. Ho-Tin-Noe B, Michel JB (2011) Initiation of angiogenesis in atherosclerosis: smooth muscle cells as mediators of the angiogenic response to atheroma formation. Trends Cardiovasc Med 21(7):183-187
26. Hofmann F (2005) The biology of cyclic GMP-dependent protein kinases. J Biol Chem 280(1):1-4
27. Holaj R, Zelinka T, Wichterle D, Petrak O, Strauch B, Widimsky J Jr (2007) Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 25(7):1451-1457
28. Hyman DJ, Taffet GE (2009) Blood pressure control in the elderly: can you have too much of a good thing? Curr Hypertens Rep 11(5):337-342
29. Iqbal J, Macdonald LJ, Low L, Seckl JR, Yau CW, Walker BR, Hadoke PW (2012) Contribution of endogenous glucocorticoids and their intravascular metabolism by 11beta-HSDs to postangioplasty neointimal proliferation in mice. Endocrinology 153(12):5896-5905
30. Ivanes F, Susen S, Mouquet F, Pigny P, Cuilleret F, Sautiere K, Collet JP, Beygui F, Hennache B, Ennezat PV et al (2012) Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J 33(2):191-202
31. Jaffe IZ, Mendelsohn ME (2005) Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 96(6):643-650
32. Jaffe IZ, Newfell BG, Aronovitz M, Mohammad NN, McGraw AP, Perreault RE, Carmeliet P, Ehsan A, Mendelsohn ME (2010) Placental growth factor mediates aldosterone-dependent vascular injury in mice. J Clin Invest 120(11):3891-3900
33. Jaffe IZ, Tintut Y, Newfell BG, Demer LL, Mendelsohn ME (2007) Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol 27(4):799-805
34. Johnson RC, Leopold JA, Loscalzo J (2006) Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 99(10):1044-1059
35. Keidar S, Hayek T, Kaplan M, Pavlotzky E, Hamoud S, Coleman R, Aviram M (2003) Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 41(6):955-963
36. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M (2004) Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109(18):2213-2220
37. Krug AW, Allenhofer L, Monticone R, Spinetti G, Gekle M, Wang M, Lakatta EG (2010) Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways. Hypertension 55(6):1476-1483
38. Lacolley P, Safar ME, Lucet B, Ledudal K, Labat C, Benetos A (2001) Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 37(2):662-667
39. Leopold JA (2009) Rapid aldosterone signaling and vascular reactivity: relax or don't do it. J Cardiovasc Pharmacol 54(6):465-467
40. Levy DG, Rocha R, Funder JW (2004) Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 89(6):2736-2740
41. Linz W, Heitsch H, Scholkens BA, Wiemer G (2000) Long-term angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive rats. Hypertension 35(4):908-913
42. Logan AG (2011) Hypertension in aging patients. Expert Rev Cardiovasc Ther 9(1):113-120
43. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP (1992) Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 71(3):503-510
44. Luo W, Meng Y, Ji HL, Pan CQ, Huang S, Yu CH, Xiao LM, Cui K, Ni SY, Zhang ZS et al (2012) Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat. PLoS One 7(3):e34230
45. Luther JM, Luo P, Wang Z, Cohen SE, Kim HS, Fogo AB, Brown NJ (2012) Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury. Kidney Int 82(6):643-651
46. Maron BA, Zhang YY, Handy DE, Beuve A, Tang SS, Loscalzo J, Leopold JA (2009) Aldosterone increases oxidant stress to impair guanylyl cyclase activity by cysteinyl thiol oxidation in vascular smooth muscle cells. J Biol Chem 284(12):7665-7672
47. McCurley A, Jaffe IZ (2012) Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 350(2):256-265
48. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, Chambon P, Hill MA, Dorrance AM, Mendelsohn ME, Jaffe IZ (2012) Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 18(9):1429-1433
49. McGraw AP, Bagley J, Chen W, Galayda C, Nickerson H, Armani A, Caprio M, Carmeliet P, Jaffe IZ (2013) Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism. J Am Heart Assoc 2:e000018
50. Mendelsohn ME (2005) In hypertension, the kidney is not always the heart of the matter. J Clin Invest 115(4):840-844
51. Michea L, Delpiano AM, Hitschfeld C, Lobos L, Lavandero S, Marusic ET (2005) Eplerenone blocks nongenomic effects of aldosterone on the Na+/H + exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 146(3):973-980
52. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45(8):1243-1248
53. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M (2005) Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 97(5):434-442
54. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, Kimura S, Yukimura T, Kiyomoto H, Kohno M et al (2005) Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 16(10):2906-2912
55. Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, Schiffrin EL, Touyz RM (2008) Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 28(8):1511-1518
56. Nagai Y, Metter EJ, Earley CJ, Kemper MK, Becker LC, Lakatta EG, Fleg JL (1998) Increased carotid artery intimal-medial thickness in asymptomatic older subjects with exercise-induced myocardial ischemia. Circulation 98(15):1504-1509
57. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T (2006) Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47(6):1084-1093
58. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M (2006) Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47(4):656-664
59. Nariai T, Fujita K, Mori M, Katayama S, Hori S, Matsui K (2012) Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats. Pharmacology 89(1-2):44-52
60. Nariai T, Fujita K, Mori M, Katayama S, Hori S, Matsui K (2012) SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats. J Cardiovasc Pharmacol 59(5):458-464
61. Newfell BG, Iyer LK, Mohammad NN, McGraw AP, Ehsan A, Rosano G, Huang PL, Mendelsohn ME, Jaffe IZ (2011) Aldosterone regulates vascular gene transcription via oxidative stress-dependent and -independent pathways. Arterioscler Thromb Vasc Biol 31(8):1871-1880
62. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr (1999) Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340(1):14-22
63. Orlandi A, Bennett M (2010) Progenitor cell-derived smooth muscle cells in vascular disease. Biochem Pharmacol 79(12):1706-1713
64. Orr AW, Hastings NE, Blackman BR, Wamhoff BR (2010) Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. J Vasc Res 47(2):168-180
65. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D et al (2001) The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 15(1):79-87
66. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709-717
67. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL (2003) Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 42(1):49-55
68. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P (2002) Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105(18):2212-2216
69. Rautureau Y, Paradis P, Schiffrin EL (2011) Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids 76(9):834-839
70. Raz-Pasteur A, Gamliel-Lazarovich A, Coleman R, Keidar S (2012) Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 60(6):508-512
71. Rita OD, Hackam DG, Spence JD (2012) Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. Can J Cardiol 28:706-711
72. Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Muiesan P, Giulini SM, Agabiti-Rosei E (1996) Vascular hypertrophy and remodeling in secondary hypertension. Hypertension 28(5):785-790
73. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E et al (2011) HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19(1):31-44
74. Roncal C, Buysschaert I, Gerdes N, Georgiadou M, Ovchinnikova O, Fischer C, Stassen JM, Moons L, Collen D, De Bock K et al (2010) Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions. Cardiovasc Res 86(1):29-36
75. Ronzaud C, Loffing J, Bleich M, Gretz N, Grone HJ, Schutz G, Berger S (2007) Impairment of sodium balance in mice deficient in renal principal cell mineralocorticoid receptor. J Am Soc Nephrol 18(6):1679-1687
76. Ronzaud C, Loffing J, Gretz N, Schutz G, Berger S (2011) Inducible renal principal cell-specific mineralocorticoid receptor gene inactivation in mice. Am J Physiol Renal Physiol 300(3):F756-F760
77. Sanz-Rosa D, Cediel E, de las Heras N, Miana M, Balfagon G, Lahera V, Cachofeiro V (2005) Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFkappaB/IkappaB system. J Hypertens 23(6):1167-1172
78. Sanz-Rosa D, Oubina MP, Cediel E, De las Heras N, Aragoncillo P, Balfagon G, Cachofeiro V, Lahera V (2005) Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences. Antioxid Redox Signal 7(9-10):1294-1301
79. Somlyo AP, Somlyo AV (1994) Signal transduction and regulation in smooth muscle. Nature 372(6503):231-236
80. Steppan J, Barodka V, Berkowitz DE, Nyhan D (2011) Vascular stiffness and increased pulse pressure in the aging cardiovascular system. Cardiol Res Pract 2011:263585
81. Stolarz-Skrzypek K, Kuznetsova T, Thijs L, Tikhonoff V, Seidlerova J, Richart T, Jin Y, Olszanecka A, Malyutina S, Casiglia E et al (2011) Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA 305(17):1777-1785
82. Taylor RS, Ashton KE, Moxham T, Hooper L, Ebrahim S (2011) Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review). Am J Hypertens 24(8):843-853
83. Ungvari Z, Kaley G, de Cabo R, Sonntag WE, Csiszar A (2010) Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci 65(10):1028-1041
84. Van Belle E, Bauters C, Wernert N, Hamon M, McFadden EP, Racadot A, Dupuis B, Lablanche JM, Bertrand ME (1995) Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist. Cardiovasc Res 29(1):27-32
85. Vinson GP, Coghlan JP (2010) Expanding view of aldosterone action, with an emphasis on rapid action. Clin Exp Pharmacol Physiol 37(4):410-416
86. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL (2002) Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40(4):504-510
87. Vukusich A, Kunstmann S, Varela C, Gainza D, Bravo S, Sepulveda D, Cavada G, Michea L, Marusic ET (2010) A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol 5(8):1380-1387
88. Wakabayashi K, Suzuki H, Sato T, Iso Y, Katagiri T, Takeyama Y (2006) Eplerenone suppresses neointimal formation after coronary stent implantation in swine. Int J Cardiol 107(2):260-266
89. Wang M, Takagi G, Asai K, Resuello RG, Natividad FF, Vatner DE, Vatner SF, Lakatta EG (2003) Aging increases aortic MMP-2 activity and angiotensin II in nonhuman primates. Hypertension 41(6):1308-1316
90. Wang M, Zhang J, Jiang LQ, Spinetti G, Pintus G, Monticone R, Kolodgie FD, Virmani R, Lakatta EG (2007) Proinflammatory profile within the grossly normal aged human aortic wall. Hypertension 50(1):219-227
91. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A (2001) Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 104(4):467-472
92. Wendler A, Albrecht C, Wehling M (2012) Nongenomic actions of aldosterone and progesterone revisited. Steroids 77(10):1002-1006
93. Widimsky J Jr, Strauch B, Petrak O, Rosa J, Somloova Z, Zelinka T, Holaj R (2012) Vascular disturbances in primary aldosteronism: clinical evidence. Kidney Blood Press Res 35(6):529-533
94. Wu SY, Yu YR, Cai Y, Jia LX, Wang X, Xiao CS, Tang CS, Qi YF (2012) Endogenous aldosterone is involved in vascular calcification in rat. Exp Biol Med (Maywood) 237(1):31-37
95. Xiao F, Puddefoot JR, Vinson GP (2000) Aldosterone mediates angiotensin II-stimulated rat vascular smooth muscle cell proliferation. J Endocrinol 165(2):533-536
96. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, Group E-HS (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11-21
97. Zhou X, Crook MF, Sharif-Rodriguez W, Zhu Y, Ruben Z, Pan Y, Urosevic-Price O, Wang L, Flattery AM, Forrest G et al (2011) Chronic antagonism of the mineralocorticoid receptor ameliorates hypertension and end organ damage in a rodent model of salt-sensitive hypertension. Clin Exp Hypertens 33(8):538-547